Loading...
Market
Will Japan see a significant reduction in COVID-19 cases by June 30, 2025 due to the new mRNA vaccine?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Japan's Ministry of Health, Labor and Welfare official reports
Story
Japan Approves CSL and Arcturus Therapeutics' Updated mRNA COVID-19 Vaccine for JN.1 Strain, Distributed by Meiji Seika Pharma
Sep 13, 2024, 12:04 PM
Japan's Ministry of Health, Labor and Welfare has approved CSL and Arcturus Therapeutics' updated self-amplifying mRNA COVID-19 vaccine for protection against the JN.1 strain. The vaccine will be distributed in Japan by Meiji Seika Pharma. This approval marks a significant step in Japan's efforts to combat the ongoing pandemic, leveraging advanced mRNA technology to enhance immunity against emerging strains. CSL and Meiji Seika Pharma are key players in this initiative.
View original story
Similar markets
Continued use without changes • 25%
Usage restrictions for certain age groups • 25%
Temporary suspension • 25%
Permanent ban • 25%
New regulations on mRNA vaccines • 25%
Public health advisory • 25%
No action taken • 25%
Further studies commissioned • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
Unchanged • 25%
Yes • 50%
No • 50%
